Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05921253 · ClinicalTrials.gov registry record · Early Phase 1
Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy
A Early Phase 1 study of Breast Cancer and Lymphoma, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 104
- Enrollment target
- 2
- Study locations
NCT05921253: Recruiting Early Phase 1 study of Breast Cancer and Lymphoma, sponsored by University of Oklahoma.
NCT05921253 is a Early Phase 1 study of Breast Cancer and Lymphoma that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 104 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05921253, a Early Phase 1 study of Breast Cancer and Lymphoma, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 104 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.
Primary Outcome
An echocardiogram will be performed on patients at baseline and at follow up (14 days after start of intervention). The percentage change of GLS and left ventricular ejection fraction (LVEF) will be compared at baseline and follow up in patients receiving cardiotoxic chemotherapy.
Conditions Studied
Interventions
- DEVICE PARASYM neuromodulation device
Study Locations (2)
Oklahoma
- Stephenson Cancer Center - Oklahoma City
- Stephenson Cancer Center- Tulsa - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2023-12-01 |
| Est. Completion | 2027-09 |
| Phase | Early Phase 1 |
What NCT05921253 shows while recruiting
NCT05921253 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which PARASYM neuromodulation device is the first listed.
NCT05921253 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05921253 about?
NCT05921253 is a clinical study titled "Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy". This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.
What is the current status of trial NCT05921253?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 104 participants. The study started on 2023-12-01. Estimated completion is 2027-09.
What conditions does trial NCT05921253 study?
This clinical trial studies the following conditions: Breast Cancer, Lymphoma.
What interventions are being tested in trial NCT05921253?
The interventions under investigation include: PARASYM neuromodulation device (DEVICE).
Who is sponsoring clinical trial NCT05921253?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05921253 being conducted?
This trial has 2 study locations across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05921253's enrollment target sits among peer trials
104 553rd of 1224 higher than 669 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
RECRUITING · Early Phase 1
-
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
RECRUITING · Early Phase 1
-
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
RECRUITING · Early Phase 1
-
FES BPET-DBT in Newly Diagnosed Breast Cancer
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
RECRUITING · Early Phase 1
-
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI